COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals
Pancreatology
; 20:20, 2021.
Article
in English
| MEDLINE | ID: covidwho-1208775
ABSTRACT
BACKGROUND:
COVID-19 pandemic-related disruptions to EUS-based pancreatic cancer surveillance in high-risk individuals remain uncertain.METHODS:
Analysis of enrolled participants in the CAPS5 Study, a prospective multicenter study of pancreatic cancer surveillance in high-risk individuals.RESULTS:
Amongst 693 enrolled high-risk individuals under active surveillance, 108 (16%) had an EUS scheduled during the COVID-19 pandemic-related shutdown (median length of 78 days) in the spring of 2020, with 97% of these procedures being canceled. Of these canceled surveillance EUSs, 83% were rescheduled in a median of 4.1 months, however 17% were not rescheduled after 6 months follow-up. Prior history of cancer was associated with increased likelihood of rescheduling. To date no pancreatic cancer has been diagnosed among those whose surveillance was delayed.CONCLUSIONS:
COVID-19 delayed pancreatic cancer surveillance with no adverse outcomes in efficiently rescheduled individuals. However, 1 in 6 high-risk individuals had not rescheduled surveillance, indicating the need for vigilance to ensure timely surveillance rescheduling.
Full text:
Available
Collection:
Databases of international organizations
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
Pancreatology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS